Search
for
Sort by
Research 30 of 1000+
- Store-and-forward teledermatology improves care and reduces dermatology referrals from walk-in clinics: A retrospective descriptive study
- Teledermatology in the COVID-19 pandemic: A systematic review
- Part I: Accuracy of Teledermatology in Inflammatory Dermatoses
- Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
- Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
- Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
- Teledermatology: An updated overview of clinical applications and reimbursement policies
- Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
- George's Story
- 5α-Reduced glucocorticoids: a story of natural selection
- Why Do Promising Therapies Stall in Development and How Can We Move Them Forward?
- Induction of Vascular Endothelial Growth Factor Messenger Ribonucleic Acid Expression in Stored Micrografts by Aminoguanidine
- To Explore the Treatment of Seborrheic Alopecia Based on the Theory of "Healthy Qi is Stored Inside, Evil Can't be Done"
- Azimuthal Scattering from Elliptical Hair Fibers
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- Analyzing the role of tofacitinib in treatment of alopecia areata: A retrospective analysis from a tertiary care center of North India
- In reply
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- The human gut chemical landscape predicts microbe-mediated biotransformation of foods and drugs
- Tumor Necrosis Factor-Alpha and Polycystic Ovarian Syndrome: A Clinical, Biochemical, and Molecular Genetic Study
- Guidelines for clinical trials of frontal fibrosing alopecia: consensus recommendations from the International FFA Cooperative Group (IFFACG)*
- Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
- Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis
- Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
- Male-pattern baldness and incident coronary heart disease and risk factors in the Heinz Nixdorf Recall Study
- MP73-14 TRANSURETHRAL RESECTION URINARY RETENTION PREDICTOR (TURP) SCORE: A NOVEL PERIOPERATIVE PREDICTOR OF POST-OPERATIVE URINARY RETENTION
- COVID-19: A catalyst for innovative hybrid teledermatology workflows to increase access and improve patient care at a large group practice
- 52898 Among scalp non-responder patients with eyebrow/eyelash regrowth in the first year, continued treatment with baricitinib resulted in meaningful scalp responses for patients with severe alopecia areata
- 49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2
- A new era for alopecia areata: New treatments and improved knowledge of the condition